Myriad Genetics (NASDAQ:MYGN) signs an agreement with Cephalon, a subsidiary of Teva...

Myriad Genetics (NASDAQ:MYGN) signs an agreement with Cephalon, a subsidiary of Teva Pharmaceutical (NYSE:TEVA), to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study. Myriad has entered into similar agreements with Abbott (NYSE:ABT), Astra Zeneca (NYSE:AZN) and BioMarin (NASDAQ:BMRN) to provide similar diagnostic testing.